Does Dr. COURTNEY BLOCKER have financial conflicts of interest?

Dr. COURTNEY BLOCKER (FNP-C) has received a total of $709 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $709 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. COURTNEY BLOCKER?

According to CMS Open Payments data, Dr. COURTNEY BLOCKER received funding from CALLIDITAS THERAPEUTICS US ($153), AKEBIA THERAPEUTICS ($129), and OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION ($123).

Does Dr. COURTNEY BLOCKER receive research grants or speaking fees?

Dr. COURTNEY BLOCKER has received $709 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. COURTNEY BLOCKER

FNP-CReal-Time Hydrated

Specialty: Nurse Practitioner, Family

Practice Location: CHARLOTTE, NC 28277

NPI Number: 1134534399

LIFETIME INDUSTRY VALUE

$709

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BLOCKER is a verified Nurse Practitioner, Family practitioner based in CHARLOTTE, NC.

Between 2021 and 2025, Dr. BLOCKER had an overall industry promotional and research financial footprint of $709 as recorded in the federal CMS Open Payments database.

$709 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BLOCKER's primary funding source is CALLIDITAS THERAPEUTICS US, which accounts for $153 (representing 21.6% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

CALLIDITAS THERAPEUTICS US

Rank 1

$153

21.6%

AKEBIA THERAPEUTICS

Rank 2

$129

18.2%

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION

Rank 3

$123

17.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.